UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
The Latest on: Vaccine production
via Google News
The Latest on: Vaccine production
- Another Experimental Covid-19 Vaccine Seems Effective, Doesn't Need Extreme Cold Storageon November 23, 2020 at 9:27 am
On Monday, researchers in the UK became the latest to announce promising results from their experimental vaccine candidate against covid-19. In the data seen so far, the vaccine appeared to be at ...
- Hungary To Test Russian Coronavirus Vaccineon November 23, 2020 at 9:19 am
Foreign Minister Peter Szijjarto says Hungary is pressing ahead with testing on a Russian coronavirus vaccine after being the first European country to receive samples of the Sputnik-V last week.
- The Latest: Germany's CureVac signs contract for new vaccineon November 23, 2020 at 9:15 am
German pharmaceutical company CureVac says it has signed a contract to produce major quantities of a COVID-19 vaccine under development in the Netherlands. The Tuebingen company said Monday it had ...
- Oxford vaccine results are in: Now we need to make sure it is usedon November 23, 2020 at 9:02 am
The Oxford vaccine—developed in partnership with AstraZeneca—stops 70% of people developing COVID symptoms. And, depending on how the doses are given, may even protect up to 90% of people. This ...
- Brazil to start production of AstraZeneca vaccine by January, says biomedical centeron November 23, 2020 at 8:29 am
Brazil's biomedical center Fiocruz expects to start producing the AstraZeneca vaccine against COVID-19 in December or January, its production vice-president Marco Krieger said in a TV interview on ...
- Astra-Oxford Vaccine Found Effective in Preventing Covidon November 23, 2020 at 8:18 am
A Covid-19 vaccine developed by the University of Oxford and AstraZeneca Plc prevented a majority of people from getting the disease in a large trial, another promising development in the quest to end ...
- Oxford-AstraZeneca COVID Vaccine Is 70% Effective on Average in Preventing the Viruson November 23, 2020 at 8:10 am
AstraZeneca on Monday said an interim analysis of clinical trials showed its coronavirus vaccine has an average efficacy of 70% in protecting against the virus.
- AstraZeneca's Covid vaccine might seem less effective than its peers — but it has some advantageson November 23, 2020 at 7:29 am
AstraZeneca's vaccine appears to have an advantage when it comes to storage, affordability and distribution, Jefferies analysts said.
- Healthcare Innovator Sterilis Solutions Increases Production to Offer Sustainable Option for COVID-19 Vaccine Wasteon November 23, 2020 at 6:12 am
Sterilis Solutions LLC, an innovator in regulated medical waste management, has increased their production volume to assist in on-site remediation for the COVID-19 vaccine due early next year. By ...
via Bing News